- Home
- ABSI vs CYRX Comparison
ABSI vs CYRX Comparison
Compare ABSI & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABSI | CYRX |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | United States |
| Employees | N/A | 1100 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.9M | 421.6M |
| IPO Year | 2021 | 2008 |
Fundamental Metrics
Financial Performance| Metric | ABSI | CYRX |
|---|---|---|
| Price | $2.48 | $8.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $7.98 | ★ $12.94 |
| AVG Volume (30 Days) | ★ 2.4M | 358.4K |
| Earning Date | 01-01-0001 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 21.67 | ★ 156.22 |
| EPS | N/A | ★ 1.40 |
| Revenue | $4,534,000.00 | ★ $176,177,000.00 |
| Revenue This Year | $10.72 | $9.71 |
| Revenue Next Year | $313.07 | $9.56 |
| P/E Ratio | ★ N/A | $5.75 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.01 | $4.63 |
| 52 Week High | $5.23 | $11.45 |
Technical Indicators
Market Signals| Indicator | ABSI | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.19 | 37.93 |
| Support Level | N/A | $6.57 |
| Resistance Level | $2.88 | $8.45 |
| Average True Range (ATR) | 0.17 | 0.50 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 29.63 | 27.14 |
Price Performance
Historical ComparisonAbout ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.